HBM Healthcare Investments AG: HBM portfolio company Swixx BioPharma and Lundbeck sign multi-regional partnership in the field of CNS
HBM Healthcare Investments AG / Key word(s): Partnership HBM portfolio company Swixx BioPharma and Lundbeck sign multi-regional partnership in the field of CNS 10.09.2025 / 08:35 CET/CEST
HBM Healthcare Investments, a leading investor in global healthcare companies, announces that its portfolio company Swixx BioPharma and its affiliated companies (Swixx) have signed a transformative, multi-regional distribution and services agreement with H. Lundbeck A/S.
Under the agreement, Swixx will distribute and commercialize Lundbeck's entire portfolio of central nervous system (CNS) therapies in selected markets across three key regions: Southeast Europe (including Israel and Russia), Turkey, and Latin America. This multi-regional partnership encompasses novel and mature therapies for psychiatric and neurological disorders and solidifies Swixx's position as a major player in CNS therapeutics. It also underscores the growing trend in the industry toward outsourcing commercial activities in emerging markets.
The partnership exemplifies Swixx's ability to create value through local expertise, operational excellence, and strategic vision—an approach that aligns with HBM Healthcare Investments' commitment to supporting outstanding entrepreneurs and innovative companies.
The privately held Swixx is the largest holding in the HBM portfolio. HBM Healthcare Investments has been a significant shareholder in the company since 2017, with a 25.1 percent stake.
About Swixx Group
The Swixx Group is one of the largest commercialization platforms representing the portfolios of pharmaceutical companies in markets they do not wish to enter or from which they wish to withdraw. The Swixx Group's companies and subsidiaries operate in several countries in Central and Eastern Europe, Greece, Eurasia, several CIS countries, the Middle East, and Latin America. With a presence in 46 countries, more than 1,700 employees, and revenues exceeding €1.2 billion in 2024, the group is one of the fastest-growing independent biopharma commercialization platforms worldwide. Swixx has brought together outstanding talent in the fields of rare diseases, oncology-hematology, specialty medicine, vaccines, and self-medication under one roof. Further information about Swixx can be found at: www.swixxbiopharma.com.
About Lundbeck
Lundbeck is a global biopharmaceutical company dedicated exclusively to brain health. With over 70 years of experience in neuroscience, the company develops transformative therapies for neurological and psychiatric disorders. Lundbeck's research and development activities focus on complex brain disorders and, building on its strong position in psychiatry and neurology, also cover neuro-specialty areas and rare neurological diseases. Lundbeck is headquartered in Denmark and employs approximately 5,700 people in more than 50 countries. The company's products are available in over 80 markets.
Contact For further information please contact Dr. Andreas Wicki, +41 41 710 75 77,
End of press releases
nachrichten-aktien-europa
